RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Public ClinicalTrials.gov record NCT02489903. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to explore the potential of the epigenetic agent RRx-001 to sensitize patients who previously received and now have failed a platinum based doublet regimen. RRx-001 is administered with autologous blood once weekly followed by or in combination with reintroduction of platinum-based doublet therapy.
Study identification
- NCT ID
- NCT02489903
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Interventions
- RRx-001 Drug
- Cisplatin Drug
- Etoposide Drug
- Carboplatin Drug
- Irinotecan Drug
- Vinorelbine Drug
- Doxil Drug
- Gemcitabine Drug
- Taxane Drug
- Paclitaxel Drug
- Nab-Paclitaxel Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2015 (Actual)
- Primary completion
- Dec 6, 2021 (Actual)
- Completion
- Dec 6, 2021 (Actual)
- Last update posted
- Mar 17, 2025
2015 – 2021
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94304 | — |
| VA Connecticut Cancer Center | West Haven | Connecticut | 06516 | — |
| Memorial Hospital of South Bend | South Bend | Indiana | 46601 | — |
| Baptist Health | Lexington | Kentucky | 40503 | — |
| Walter Reed National Military Medical Center | Bethesda | Maryland | 20889 | — |
| Henry Ford Allegiance Health | Jackson | Michigan | 49201 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| University of Cincinnati Cancer Institute | Cincinnati | Ohio | 45267 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| West Virginia University | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02489903, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2025 · Synced Oct 30, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02489903 live on ClinicalTrials.gov.